Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quantum Cyber ( (QUCY) ) just unveiled an update.
In February 2026, Quantum Cyber’s board decided to wind down its ColoAlert colorectal cancer screening business and halt development of its next-generation colorectal cancer screening candidates, terminating staff primarily dedicated to those projects and pivoting strategic focus to pancreatic cancer screening. On March 28, 2026, the company sold the ColoAlert intellectual property, and on April 9, 2026 it agreed to sell the next-generation colorectal cancer screening IP to an Italian buyer for $1.25 million, with closing expected by April 23, 2026, subject to customary conditions, and plans to use proceeds to settle liabilities and fund general corporate needs.
These divestitures are intended to streamline operations without affecting other projects, as the company continues advancing its pancreatic cancer detection candidate and assessing post-quantum cybersecurity prospects. Financially, Quantum Cyber reported stockholders’ equity of $641,600 as of December 31, 2025, below Nasdaq’s $2.5 million minimum, but it received $6 million from preferred share sales in February and March 2026 and reduced monthly expenses through the wind-down, leading management to believe the firm now complies with the exchange’s equity requirement and improving its near-term listing outlook.
The most recent analyst rating on (QUCY) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Quantum Cyber stock, see the QUCY Stock Forecast page.
Spark’s Take on QUCY Stock
According to Spark, TipRanks’ AI Analyst, QUCY is a Neutral.
The score is primarily constrained by weak financial performance, including persistent losses, negative operating cash flow, and high leverage. Technicals offer only modest support with short-term improvement but a longer-term downtrend. Valuation impact is neutral due to missing P/E and dividend yield data.
To see Spark’s full report on QUCY stock, click here.
More about Quantum Cyber
Quantum Cyber operates in the medical diagnostics and cybersecurity sectors, having previously focused on colorectal cancer screening products such as its flagship ColoAlert test in European markets. The company is now concentrating on developing a pancreatic cancer detection product candidate while also exploring opportunities in post-quantum cybersecurity, positioning itself at the intersection of healthcare innovation and advanced cyber protection.
Average Trading Volume: 593,220
Technical Sentiment Signal: Sell
Current Market Cap: $6.33M
See more data about QUCY stock on TipRanks’ Stock Analysis page.